Pregabalin and gabapentin for chronic low back pain without radiculopathy: a systematic review

Abstract

Background Chronic low back pain (CLBP) is a global health problem, and gabapentin and pregabalin are often used in the treatment of patients without associated radiculopathy or neuropathy. Therefore, determining their efficacy and safety is of enormous value.

Objective To examine the efficacy and safety of using gabapentin and pregabalin for CLBP without radiculopathy or neuropathy.

Methods We performed a search on the CENTRAL, MEDLINE, EMBASE, LILACS, and Web of Science data bases for clinical trials, cohorts, and case-control studies that evaluated patients with CLBP without radiculopathy or neuropathy for at least eight weeks. The data were extracted and inserted into a previously-prepared Microsoft Excel spreadsheet; the outcomes were evaluated using the Cochrane RoB 2 tool, and the quality of evidence, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

Results Of the 2,230 articles identified, only 5 were included, totaling 242 participants. In them, pregabalin was slightly less efficacious than amitriptyline, the combination of tramadol/acetaminophen, and celecoxib, and pregabalin added to celecoxib showed no benefit when compared to celecoxib alone (very low evidence for all). On the other hand, although one study with gabapentin did not support its use in a general sample of patients with low back pain, another found a reduction in the pain scale and improved mobility (moderate evidence). No serious adverse events were observed in any of the studies.

Conclusion Quality information to support the use of pregabalin or gabapentin in the treatment of CLBP without radiculopathy or neuropathy is lacking, although results may suggest gabapentin as a viable option. More data is needed to fill this current gap in knowledge.

Resumo

Antecedentes Dor lombar crônica (DLC) é um problema de saúde global, e a gabapentina e a pregabalina são frequentemente utilizadas no tratamento de pacientes sem radiculopatia ou neuropatia associada. Por isso, determinar sua eficácia e segurança é de enorme valor.

Objetivo Examinar a eficácia e segurança do uso de gabapentina e pregabalina no tratamento da DLC sem radiculopatia ou neuropatia.

Métodos Realizamos uma pesquisa nas bases de dados CENTRAL, MEDLINE, EMBASE, LILACS e Web of Science por ensaios clínicos, coortes e estudos de caso e controle que avaliassem pacientes com DLC sem radiculopatia ou neuropatia por pelo menos oito semanas. Os dados foram extraídos e inseridos em uma planilha previamente elaborada no programa Microsoft Excel; os desfechos foram avaliados com a ferramenta RoB 2 tool da Cochrane, e a qualidade das evidências, pelo sistema Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Resultados Dos 2.230 artigos identificados, apenas 5 foram incluídos, com um total de 242 participantes. Neles, a pregabalina foi ligeiramente menos eficaz do que a amitriptilina, a combinação de tramadol/acetaminofeno, e o celecoxibe, assim como a pregabalina adicionada ao celecoxibe não mostrou benefício em comparação ao uso isolado de celecoxibe (evidência muito baixa para todos). Quanto à gabapentina, embora um estudo não respalde seu uso para uma amostra geral de pacientes com lombalgia, outro encontrou redução na escala de dor e melhora da mobilidade (evidência moderada). Nenhum evento adverso grave foi observado nos estudos.

Conclusão Há carência de informações de qualidade que sustentem o uso de pregabalina ou gabapentina no tratamento da DLC sem radiculopatia ou neuropatia, embora resultados possam sugerir que a gabapentina é uma opção viável. Mais dados são necessários para preencher essa atual lacuna no conhecimento.

Keywords

Low Back Pain - Back Pain - Chronic Pain - Pregabalin - Gabapentin - Systematic Review

Palavras-chave

Dor Lombar - Dor nas Costas - Dor Crônica - Pregabalina - Gabapentina - Revisão Sistemática

Authors' Contributions

RTT: conceptualization, data curation, formal analysis, methodology, resources, visualization, writing – original draft, and writing – review and editing; AWP: conceptualization, formal analysis, methodology, project administration, supervision, validation, visualization, writing – original draft, and writing – review and editing; CACO: conceptualization, data curation, formal analysis, methodology, project administration, supervision, validation, visualization, writing – original draft, and writing – review and editing.

Publication History

Received: 28 February 2022

Accepted: 31 October 2022

Article published online:
28 June 2023

• References

• 1 Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ 2006; 332 (7555): 1430-1434
• 2 Furlan AD, Malmivaara A, Chou R. et al; Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine 2015; 40 (21) 1660-1673
• 3 Hoy D, Bain C, Williams G. et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012; 64 (06) 2028-2037
• 4 Kamper SJ, Henschke N, Hestbaek L, Dunn KM, Williams CM. Musculoskeletal pain in children and adolescents. Braz J Phys Ther 2016; 20 (03) 275-284
• 5 Hartvigsen J, Christensen K, Frederiksen H. Back pain remains a common symptom in old age. a population-based study of 4486 Danish twins aged 70-102. Eur Spine J 2003; 12 (05) 528-534
• 6 Kassebaum NJ, Arora M, Barber RM. et al; GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388 (10053): 1603-1658
• 7 Vos T, Allen C, Arora M. et al; GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388 (10053): 1545-1602
• 8 Cassidy JD, Carroll LJ, Côté P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. Spine 1998; 23 (17) 1860-1866 , discussion 1867
• 9 Deyo RA, Tsui-Wu Y-J. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine 1987; 12 (03) 264-268
• 10 Pengel LHM, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ 2003; 327 (7410): 323
• 11 Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ. Outcome of low back pain in general practice: a prospective study. BMJ 1998; 316 7141 1356-1359
• 12 Knezevic NN, Candido KD, Vlaeyen JWS, Van Zundert J, Cohen SP. Low back pain. Lancet 2021; 398 (10294): 78-92
• 13 El Sissi W, Arnaout A, Chaarani MW. et al. Prevalence of neuropathic pain among patients with chronic low-back pain in the Arabian Gulf Region assessed using the leeds assessment of neuropathic symptoms and signs pain scale. J Int Med Res 2010; 38 (06) 2135-2145
• 14 Beith ID, Kemp A, Kenyon J, Prout M, Chestnut TJ. Identifying neuropathic back and leg pain: a cross-sectional study. Pain 2011; 152 (07) 1511-1516
• 15 Fishbain DA, Cole B, Lewis JE, Gao J. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med 2014; 15 (01) 4-15
• 16 Qaseem A, Wilt TJ, McLean RM. et al; Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017; 166 (07) 514-530
• 17 Skljarevski V, Desaiah D, Liu-Seifert H. et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; 35 (13) E578-E585
• 18 Skljarevski V, Ossanna M, Liu-Seifert H. et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16 (09) 1041-1048
• 19 Skljarevski V, Zhang S, Desaiah D. et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11 (12) 1282-1290
• 20 Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg 2017; 124 (01) 44-51
• 21 Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43 (13) 879-923
• 22 Shanthanna H, Gilron I, Rajarathinam M. et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLoS Med 2017; 14 (08) e1002369
• 23 Baron R, Freynhagen R, Tölle TR. et al; A0081007 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010; 150 (03) 420-427
• 24 McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. Pain Clin 2001; 13 (02) 103-107
• 25 Yildirim K, Şışecıoğlu M, Karatay S. et al. The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clin 2003; 15 (03) 213-218
• 26 Sterne JAC, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
• 27 Wiffen PJ, Derry S, Moore RA. et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017; 7 (07) CD012637
• 28 Higgins JPT, Thomas J, Chandler J. et al. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Wiley; 2019.
• 29 McCleane GJ. Gabapentin reduces chronic benign nociceptive pain: a double-blind, placebo-controlled cross-over study. Pain Clin 2000; 12 (02) 81-85
• 30 Atkinson JH, Slater MA, Capparelli EV. et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain 2016; 157 (07) 1499-1507
• 31 Kalita J, Kohat AK, Misra UK, Bhoi SK. An open labeled randomized controlled trial of pregabalin versus amitriptyline in chronic low backache. J Neurol Sci 2014; 342 (1-2): 127-132
• 32 Sakai Y, Ito K, Hida T, Ito S, Harada A. Pharmacological management of chronic low back pain in older patients: a randomized controlled trial of the effect of pregabalin and opioid administration. Eur Spine J 2015; 24 (06) 1309-1317
• 33 Romanò CL, Romanò D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009; 10 (04) 185-191
• 34 Schmidt K, Aaron W. Eds. St. Anthonys ICD.9.CM. Code book, Vols 1,2 & 3. Saint Anthony; 1996.
• 35 Bonica J. . The Management of Pain. 2nd ed. Philadelphia: Lea & Febiger; 1990.
• 36 Walsh N, Dimitru D, Ramamurthy S, Schoenfeld L. . Treatment of the patient with chronic pain. In: DeLisa J, Gans B, eds. Rehabilitation medicine: principles and practice. 2nd ed. Philadelphia: Lippincott; 1993. p. 973–95.